Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098362 | 0.81 | BACE1 (0.39) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17008348 | 0.76 | BACE1 (0.38) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL26964637 | 0.75 | BACE1 (0.44) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL29498916 | 0.75 | BACE1 (0.42) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5188479 | 0.74 | BACE1 (0.41) | BACE1CYP3A4HTTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL14841695 | 0.72 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21827648 | 0.72 | BACE1 (0.41) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1751115 | 0.72 | BACE1 (0.43) | BACE1SMN1; SMN2 | |
| SCHEMBL14461324 | 0.72 | BACE1 (0.43) | BACE1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9893844 | 0.72 | BACE1 (0.40) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | BACE1 2085/4885CYP3A4 1543/4885HTT 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.